Yksityisyysasetukset
Inderes käyttää evästeitä tarjotakseen paremman käyttökokemuksen ja henkilökohtaisemman palvelun. Hyväksymällä evästeiden käytön voimme kehittää palvelua entistä paremmin ja pystymme tarjoamaan sinua kiinnostavaa sisältöä.
  • Foorumi
  • Premium
  • Osakemarkkinat
    • PörssiReaaliaikaiset kurssit, indeksit ja markkinakehitys
    • AamukatsausPäivittäinen markkinakatsaus ja yön tärkeimmät tapahtumat
    • PörssikalenteriTulevat tulokset, listautumiset ja yritystapahtumat
    • OsinkokalenteriTulevat ja menneet osingot
  • Yhtiöt
    • YhtiötSelaa ja suodata listattujen yhtiöiden listaa
    • Löydä osakkeitaInspiraatiota seuraavaan sijoitukseesi
    • ListautumisetUudet listautumiset ja tulevat pörssiannit
    • YhtiökokouskutsutYhtiökokousten päivämäärät ja osakkeenomistajatiedot
  • Osaketutkimus
    • AnalyysiAsiantuntijoiden osakeanalyysi ja suositukset
    • ArtikkelitUutiset, näkemykset ja markkinakommentit
    • MallisalkkuInderesin mallisalkku
    • FemmeRohkeutta ja itseluottamusta sijoittamiseen
  • Opi sijoittamisesta
    • AnalyysikouluOpi lukemaan ja ymmärtämään osakeanalyysiä
    • SijoituskouluOppaita ja oppitunteja sijoitusosaamisen kasvattamiseen
    • SalkunhaltijatSijoitustietoa jokaiselle tasolle, ensiaskeleista edistyneisiin salkkustrategioihin.
    • inderesTVVideokeskus osaketutkimukselle, analyysille ja asiantuntijakommenteille
    • TranskriptitTulosjulkistusten ja sijoittajatapaamisten tekstimuotoiset tallenteet
    • OsakevertailuVertaa tunnuslukuja ja kehitystä useiden osakkeiden välillä
    • TuloskausiVertaile EPS-ennusteita toteutuneisiin tuloksiin
    • Sisäpiirin kaupatSeuraa yhtiöiden sisäpiiriläisten osto- ja myyntitoimintaa
    • LyhyeksimyyntiKatso, millä pörssiyhtiöillä on ilmoitettuja lyhyitä positioita
    • Virtuaalinen analyytikkochatEsitä kysymyksiä ja saa tekoälypohjaisia sijoitusnäkemyksiä
    • Korkoa korolle -laskuriLaske, miten säästösi kasvavat korkoa korolle -ilmiön ansiosta.
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Q&A
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Kaikki markkinat
Suomi
Ruotsi
Tanska
Norja
Uusimmat
Suositut
Seuratut

Oncopeptides, Audiocast, Q3'26

Julkaissut Inderes5.11.2026 klo 8.00
Oncopeptides

Huomio: Tämä on koneellisesti luotu transkripti ja se saattaa sisältää epätarkkuuksia.

Unknown 1
00:00 - 00:00

Head.

Sofia Heigis
00:01 - 04:30

Hello everyone, and welcome to the presentation of the Oncopeptides AB report for the third quarter of 2026. My name is Sofia Heigis and I am the CEO of Oncopeptides AB. Before we begin, please note our standard disclaimer regarding forward-looking statements. Today's presentation is led by me and our CFO, Henrik Bergentoft. Together, we will walk you through our third quarter commercial performance and the major clinical and regulatory milestones we have achieved over the past few weeks. Let's look at where we stand right now. During the third quarter, we delivered net sales of 28.5 million SEK, representing a 41% increase compared to the third quarter of 2025, when we delivered 20.2 million SEK for the first nine months of the year. Net sales reached just under 85 million SEK, up 62%, compared to the 52.6 million SEK reported for the same period last year. Also, for the first time in Oncopeptides AB history, sales for the last 12 months exceeded 100 million SEK, reaching 103.5 million SEK. Our cash position at the end of the third quarter stood at 116.8 million SEK, which was further strengthened after the period by approximately 100 million SEK in gross proceeds from the directed share issue completed in October. The positive CHMP opinion to expand Pepaxti into third-line treatment, and the potential approval by the European Commission expected to follow in Q4, could unlock significant new sales potential. We remain on track to achieve positive cash flow during 2027. Importantly, our cash flow guidance is based on our commercial operations for Pepaxti in Europe to become self-sustaining. Our clinical program in glioblastoma is ring-fenced as a separate value-creating venture, with its upcoming CMC and clinical activities funded by the 100 million SEK raised in October. Looking at some of the significant events from July to September. In September, the CHMP, the European Medicines Agency's Committee for Medicinal Products for Human Use, issued a positive opinion for the label expansion of Pepaxti into third-line treatment. We achieved our first expansion milestone in Central and Eastern Europe by receiving an official list price for Pepaxti in Slovenia. On the scientific front, we highlighted our clinical progress and presented new multiple myeloma data at the IMS annual meeting in Glasgow and in neuro-oncology. We presented preclinical and translational glioblastoma data at the EANO Congress in Rome, where we were also nominated for the prestigious EANO Poster Award for demonstrating encouraging data on overcoming resistance in preclinical models. It has also been an eventful period after the close of the quarter. First, we confirmed blood-brain-barrier penetration in humans based on initial data from the first three patients in glioblastoma. We are now conducting the window of opportunity study to move on with the clinical development of glioblastoma. We completed a directed share issue of approximately 100 million SEK. I want to thank both our new investors and our largest shareholder, HealthCap, for their continued support and trust in Oncopeptides. Finally, just yesterday, we announced that two new independent real-world studies from Spain and Italy have been accepted for presentation at the upcoming American Society of Hematology annual meeting in December. Acceptance of RWE data to be presented at ASH is demonstrating how important it is to understand how the real patients are doing on different drugs in a rapidly evolving treatment landscape. It is important to remember that these patients are commonly older, have more comorbidities, and are more frail than those in the clinical studies. With that introduction, I will now hand over to Henrik for a walkthrough of the third quarter financials.

Henrik Bergentoft
04:31 - 07:46

Thank you, Sofia. So, Q3 provides further evidence of the positive commercial trajectory we are building. Net sales reached $28.5 million, an increase of 41% year-on-year, and sales for the first nine months grew 61% to $84.9 million. Importantly, this growth continues to translate into attractive economics, with a gross margin of approximately 98% for the nine-month period. At the same time, we maintain tight cost control, which contributed to a material improvement in EBIT and net result compared with last year. Taken together, the quarter shows stronger sales, continued high gross margins and improving operating leverage. We continue to allocate capital with a clear focus on growth and value creation. Operating expenses were 66.1 million in the quarter, approximately 3% lower year on year. Sales and marketing investment of 36.5 million supports our commercial activities in Germany, Spain and Italy. We will remain focused on expanding the reach of Pepaxti. At the same time, G&A costs decreased materially to 11.7 million, reflecting disciplined overhead management and focused activities. R&D spending of 17.9 million SEK remains focused on selected high-potential opportunities, including the ongoing glioblastoma Window of Opportunity study, where we have published promising results already. Overall, we are combining continued commercial investment with lower overhead and focused pipeline execution, creating a stronger foundation for sustainable growth. We ended the quarter with 117 million SEK in cash. Following the quarter, we further strengthened our financial position through a directed share issue of 100 million before transaction costs. The financing provides dedicated capital to advance CMC activities, complete study preparations and fund the next clinical phase in glioblastoma. Meanwhile, this allows us to maintain disciplined commercial execution, moving the commercial part of Oncopeptides AB towards positive cash flow during 2027. The clear message is that Oncopeptides is entering its next phase, with growing Pepaxti sales, attractive gross margins, a more efficient cost base, and the financial capacity to advance an additional potential value driver in glioblastoma. We believe the combination of commercial momentum, improving operating leverage and upcoming clinical execution creates an increasingly compelling opportunity for Oncopeptides. And with that, I hand back over to you, Sofia.

Sofia Heigis
07:47 - 25:35

Thank you. Henrik. Let's now turn to the business update. Third quarter net sales of 28.5 million were in line with our expectations. As we also saw in previous years, the third quarter is affected by the European summer vacation period. We saw demand naturally soften during August and September. Despite this seasonal effect, we delivered 41% growth compared to Q3 last year. We have now treated more than 1,200 patients with Pepaxti across Europe since our EMA approval in 2022. These heat maps are comparing Q3 from 2023 up to 2026. Our geographic footprint and prescriber base have expanded substantially across Germany, Italy and Spain. This growing real-world clinical experience triggers independent RWE publications, which in turn fuels the peer-to-peer recommendations that are so critical to physicians managing patients. That requires individualized treatment. Following an approved label expansion into an earlier line, we would have the potential to double both our addressable patient population and the average treatment cycle length in the third line. Looking at our clinical position under our current fourth-line label, real-world data and clinical experience consistently point to three distinct patient profiles where Pepaxti makes a clear difference. First, an option for patients unable to receive immunotherapy due to comorbidities, frailty, infections, and quality of life limitations. Second, as an ideal bridge between immune-based therapies, offering non-cross-resistant disease control while allowing for T cell or antigen reset. Or antigen reset, and third, as a proven salvage option for patients who have relapsed or become refractory after BCMA or CAR-T therapies. Following a potential EMA approval, this positioning would become even stronger as part of our pre-launch activities for the third-line label expansion. We have gathered extensive insights from key opinion leaders across Europe. The feedback is remarkably consistent and confirms an unmet need in the third line for non-immunotherapy mechanisms that complement the first and second line regimens. Moving into the third-line would mean Pepaxti is a strategic option for both patients who cannot receive immunotherapy, and as an ideal bridge between immunotherapies earlier in the treatment journey. Just yesterday, we announced that two independent, multicenter, real-world studies from Spain and Italy have been accepted for presentation at ASH in December. The studies, covering in total 82 heavily pretreated patients, further validate Pepaxti's clinical utility and manageable safety profile. Both post-immunotherapy and as a bridge to subsequent immunotherapies. Let's look closer at our key markets, starting with Germany. Germany is the European market with the largest potential for us, and it is also the market where the summer vacation period had the most pronounced seasonal impact. According to September competitor sales data, the overall market in Germany was flat, meaning this is not only the case for us, but for competitors as well. Through commercial discipline and the sharpened business model we implemented earlier this year. We continue to steer our German operations steadily towards country-level profitability. In parallel, our prospective real-world evidence study, MARINA, is progressing and helping us generate experience with office-based hematologists post the hopefully positive EMA decision; the MARINA study team at IO Medical will submit an amendment for the inclusion criteria to reflect the new label, with inclusion of patients from the third line. As you can see on the map and the graph on the right, our German prescriber base continues to grow quarter over quarter. Once physicians gain clinical experience with Pepaxti, they appreciate its profile and continue to prescribe it. Our German team is fully focused on unlocking both new prescribers and earlier line usage, as we are still in later lines in Germany. Moving to Italy. Even if August and September did slow down due to the vacation period, Italy remains a key growth contributor. Italy is our most mature market in terms of clinical experience and fourth-line usage, demonstrating the highest estimated number of treatment cycles per patient based on our sales data, but also confirmed by the real-world data that will be presented at ASH. This success is driven by established market access all the way down to the hospital level, and a very positive clinical experience that drives accurate patient identification and demand. This positive real-world experience is further reinforced by the Italian multicenter study of 42 heavily pretreated patients accepted for ASH. This study demonstrates a strong 38% overall response rate and a 13.5-month median overall survival across a median of five treatment cycles, providing reliable disease control and manageable tolerability. Pepaxti enabled 67% of these patients to proceed to a subsequent treatment, including novel immunotherapies such as bispecific antibodies and CAR-T therapies. In Spain, even though the third quarter was affected by the summer vacation period, sales continued at a higher level than in the previous quarter. Our team has worked with great resilience alongside key opinion leaders to keep expanding our footprint across the countries, as illustrated by the heat map. A great example of the scientific engagements in Spain is the Spanish registry study of 40 heavily pretreated patients accepted for ASH. The study demonstrates a 32.5% overall response rate, an 8.3 month duration of response, and an encouraging 15.7 month median overall survival. Even among the subgroup of last-resort patients previously exposed to anti-BCMA and/or anti-GPRC5D immunotherapies. Treatment achieved a 26% response rate and a 23.2-month median overall survival. Looking at our broader European commercialization roadmap, our phased rollout has been built around an estimated 1.5 billion SEK annual market potential and our fourth-line label protected by market exclusivity until 2037. Phase one markets, Germany, Spain, Italy, Austria, and Greece, represent roughly 50% of that potential, where we are already established. We are actively evaluating strategic options, including new partnership discussions, to ensure we capture the full potential of Europe over time. Let's look at what a European Commission approval of our type two variation could mean in practice. Currently, Pepaxti is indicated for fourth-line-plus patients who have received at least three prior lines of therapy and are triple-class refractory; however, following a positive EC approval, Our label would expand to adult patients who have received at least two prior lines of therapy, meaning third-line and later, and whose disease is refractory to lenalidomide and their last line of therapy. Removing the triple-class refractory requirement is a major shift that could facilitate earlier and much more frequent patient identification for clinicians. This potential label expansion acts as a powerful commercial and financial multiplier across three dimensions. First, on the commercial side, removing the triple-class refractory barrier and moving to earlier lines would effectively double our addressable European patient population. And as shown in the Phase 3 OCEAN trial, earlier intervention allows patients to remain on therapy longer, doubling the average number of treatment cycles per patient in third line, which would unlock potential far beyond our 1.5 billion SEK estimate currently. Second, regarding market access and pricing, the German basket pricing approach, which averages modern third-line therapies, establishes an attractive comparative price anchor. The German rules would allow immediate launch, giving third-line patients access to Pepaxti while we are negotiating the price. This is very positive for both patients and our commercialization. Third, on medical need and scalability. Pepaxti fills a growing gap for a non-immunotherapy mode of action following first and second-line relapse, which can support our direct presence in Germany, Austria, Italy, and Spain and the value of our partnerships such as SALUS in CEE. Looking at the timeline, we have thus far executed on this regulatory process rapidly. Following our submission to EMA this summer, we received a positive CHMP opinion in September and expect the formal European Commission decision in the coming weeks, as it should follow no later than 60 days following a CHMP decision. Our immediate priority following a positive decision is to submit a German reimbursement dossier within approximately one month of the EC decision, enabling an immediate commercial launch in the third-line in Germany. In parallel, we are preparing our third-line launches in Italy and Spain and stand ready to submit our market access dossiers as soon as local procedures allow. To illustrate this at the patient level, multiple myeloma is a marathon. It is not a sprint. With each relapse, the tumor burden accelerates, and patients become increasingly frail, both from their disease and from the side effects of prior treatments. By expanding our indication to support third-line and less refractory fourth-line patients, we would be able to bring the benefits of Pepaxti to patients earlier in their disease course, when they are fitter and can stay longer on treatment. Looking at the overall treatment landscape of myeloma, it has evolved with multiple launches in the first, second, and fourth lines over the last few years. Patients now have several options with immunomodulators, anti-CD38 antibodies, proteasome inhibitors, bispecifics, CAR-Ts, and ADCs. What is important to notice is that many of these drugs are targeting BCMA and utilizing the immune system, and as many of these options are already used in earlier lines, physicians increasingly need a differentiated non-cross-resistant mode of action, like our PDC in the third line and beyond. Turning to our partnership and geographic expansion in Central and Eastern Europe. Our partner SALUS made rapid progress by securing a list price in Slovenia in line with the German list price in August. While Slovenia is a smaller market in terms of volume, it serves as a critical reference pricing anchor across the entire CEE region, providing a solid foundation as SALUS now begins to submit reimbursement dossiers in other countries. In Japan, our partnership dialogues have continued through active engagements, both remotely and in person, with multiple potential partners during the third quarter. In addition, we have met with the top KOLs in Japan and confirmed that they do see the need for Pepaxti as an option that complements immunotherapies. Japan is slightly behind in experience with immunotherapy, but the trend is clear. There are patients progressing on immunotherapy. And there are patients that cannot get immunotherapy due to comorbidities and frailty. This is also observed in Japan. Let's now move to our pipeline, where we have just recently achieved a clinical breakthrough. We have advanced our pipeline into the clinic with a focus on CNS tumors, starting with glioblastoma. The single greatest hurdle in neuro-oncology is the lack of blood-brain-barrier penetration, which causes more than 90% of systemic cancer drugs to fail because they simply cannot reach the tumor. Rather than jumping straight into a costly phase one trial, we designed the capital-efficient INSULA Window of Opportunity study of approximately ten patients at Oslo University Hospital using our approved PDC drug as a clinical probe to test membrane penetration rapidly, and in October, data from the first three patients was concluded to be positive. Let's look closer at what we announced on October 9th from the INSULA study. First, we confirmed blood-brain-barrier penetration via biopsies from resected tumor tissue. In the first patients. The first three evaluated patients demonstrated clear and consistent presence of the active compound. Meeting our primary objective, we achieved pharmacological concentrations completely in line with our preclinical models. Second, we saw a consistent and favorable safety profile. Treatment has been well-tolerated, with no major drug-related toxicity and no unexpected surgical complications. Remarkably, the first patient transitioned into the study's open-label extension and has received five monthly cycles without any new tumor-related neurological symptoms. Together, this marks a critical clinical proof of concept for our PDC platform in CNS tumors. Transforming our brain cancer program from an ambitious preclinical scientific premise into a clinically validated opportunity in a market projected to grow into the size of approximately 8 billion USD by 2035. So what will happen next? First, we will complete the pharmacokinetic analysis in cohort one, which includes five patients. Second, we have obtained approval to open cohort two from the Safety Review Committee and will, once fully recruited, conclude the pharmacodynamic data analysis, which is exploratory, but we do hope it will give us some further scientific insights. And third, we will follow the open-label patients and observe how they are doing on a PDC. The INSULA patients have recurrent glioblastoma, meaning the focus is not only on efficacy but safety, and the quality of the time they have left is also of importance. Finally, this human proof-of-concept has triggered us to advance our CMC manufacturing activities, complete clinical study preparations, and execute the next clinical development phase for our PDC pipeline in neuro-oncology. This will, of course, happen in dialogue with regulatory authorities to ensure we generate the evidence needed, while we also reach patients without any treatment options as soon as possible. With a positive CHMP opinion and the European Commission decision around the corner for Pepaxti, a human proof-of-concept in glioblastoma and dedicated financing in place. We look forward to keeping you updated on an exciting fourth quarter, and with that, I would like to thank you for listening, and we will now open up the line for questions.

Operator
25:37 - 25:53

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanius from Redeye. Please go ahead.

Richard Romanius
25:56 - 26:13

Good morning. I have a few questions. Starting with one on sales. What should be our expectations? What expectations should we have for Q4 sales compared with the sales in Q3 and year-to-date this year.

Sofia Heigis
26:16 - 27:07

Thank you for your question and good morning. So, when it comes to this, we have been launching for some years now, right. And we started with Germany, and then we added some markets. And when it comes to Q3, it is clear that the summer vacation period continues to affect our sales. So it's a bit of an outlier. If we talk about last year's Q4, that was also an outlier because then we had a strike happening in Spain and our sales dropped in December very rapidly. So, without commenting on the fourth quarter, I would expect the trend to be more similar to the year before. Of course, granted that nothing really unexpected happens.

Richard Romanius
27:09 - 27:23

Great. And. A question for Henrik. How should we view the cost base for the rest of this year and for 2027?

Henrik Bergentoft
27:25 - 28:35

Yes, Richard, thanks for that question. So we have previously guided our cost base with a reference to the actuals for 2025, where we had total operating costs just below 300 million. We expect that to be a relevant benchmark for the full year 2026 as well. But as you can see, we are running a bit lower than that. So if you do the math, you can get the expectations for the fourth quarter. Now moving into 2027, we expect that the commercial part of Oncopeptides AB will run more or less on the same cost base. But it is important to add that we are now advancing with glioblastoma into the next clinical phase, and that will also generate cost. And we will, of course, be very clear on communicating what is what. But these are two different value drivers with separate investment cases, if you will. What is that?

Richard Romanius
28:38 - 28:57

Yeah. Thanks. A final question for Sofia. How long on the base case would you expect clinical development in glioblastoma to take? So, when could the drug be on the market?

Sofia Heigis
28:58 - 30:19

We need to interact with regulatory authorities to be more specific on a timeline. But with that said, if I am going to reason a bit around glioblastoma as a disease and how it usually works, glioblastoma is, as you know, a very aggressive disease. There is a high unmet need and there is a rapid progression, with a desperate need for new drugs. So I would assume that if we continue to show good clinical progress and the evidence is positive along the way, that there is an opportunity for different regulatory mechanisms that can bring a PDC to the market rather sooner than later. So if you compare it to an average time to market, I would assume a glioblastoma development program would be much shorter, including, for example, accelerated approval in the US, a potential faster approval in geographies like Europe as well, and most likely orphan drug designation, etc. But as stated, we now have the initial data and we will, once we have some more data from the INSULA study, interact with regulatory authorities, and then we will of course keep you posted on our plans.

Richard Romanius
30:21 - 30:24

Excellent. Thanks for answering my questions.

Sofia Heigis
30:25 - 30:26

Thank you so much, Richard.

Operator
30:28 - 30:41

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Georg Tikhonov from ABG Sundal Collier. Please go ahead.

Richard Romanius
30:44 - 31:33

Yeah. Hi. Good morning. This is Georg from ABG. Congratulations on the steady progress. I have two questions, please. So firstly, I am wondering if you would be able to comment on how the development of Pepaxti has been so far in Q4, and secondly, in glioblastoma, I am wondering if you could perhaps elaborate on what is in your base case regarding the patient subgroup and the treatment line that you will be targeting. Of course, given that you showed the panel that is in the drug in the platform. Thank you.

Sofia Heigis
31:33 - 35:50

Thank you so much and good morning. So when it comes to Q4, I would basically like to repeat my answer as I gave to Ricard. So we are not commenting on the current quarter, but if you look at the trend of the different quarters, in Q3, we did see encouraging growth year over year, and we are very happy about that because it shows the need for and the progress of Pepaxti in Europe. But if you look more short term and quarter over quarter. It is, of course, a weaker quarter than Q2 when it comes to Q4. It is commonly stronger than Q3, and the trend is turning up. But as I said, last year in Q4, we had a very unfortunate strike in Spain, and we had a bit of a slower development in Germany. So we were surprised. We do not anticipate those kinds of surprising events again. But of course, the nature of surprises is that you do not know about them. Right? So, when it comes to Q4, I would assume, granted nothing unexpected is happening, that we are more into the 2024 trend rather than the 2025 trend. When it comes to your question on glioblastoma, it is too early to say exactly what subgroup we will address. But of course, we have different hypotheses based on our preclinical data. And that is what I can reason around at this time point. And then it is important to note that, as we said before, we have to interact with regulatory authorities to agree on a clinical development program, including then, of course, the target population. But if we look at our preclinical data, I would like to allude to what we are seeing there. So glioblastoma is a very resistant disease. And there are different types of mutations. One quite common mutation is that you have a mutated MGMT promoter. That means that you have an upregulation of DNA repair. And as alkylators and temozolomide, that is the standard of care today. That is an alkylator or damages the DNA. The up-regulation of the repair mechanism is then preventing the efficacy of the drug. If we look at our preclinical data, it looks as if we have the same result in killing tumor cells with both mutated and without MGMT mutations. That is, we can overcome this resistance. So it doesn't matter if there is an up-regulation of the DNA repair because this is most likely due to our mode of action. Due to that, we are damaging the DNA double-stranded in both the mitochondria and in the nucleus. And this up-regulation of DNA repair does not seem to be effective in the mitochondria. I am looking then to your question, and what population would we target? I mean, 60% of all patients already in the first line do have this mutation and have limited efficacy of today's standard of care. So obviously, we will bring our preclinical data to the regulators, and we will discuss with them whether it would be possible to go for a first-line population fairly early on in the clinical development program. With that said, when you start the INSULA study, and most likely in phase one, you would have to go for recurrent glioblastoma as it is a first-in-man study. When you do a dose-finding study with a new PDC. So that was a quite long answer. Trying to educate a bit about how we are reasoning and our preclinical data. But was that clear enough for you, or do you have any follow-up questions?

Richard Romanius
35:52 - 35:58

Well, definitely, I appreciate that detailed response. So, yeah, thanks again.

Sofia Heigis
35:59 - 36:00

Thank you so much for your questions.

Operator
36:03 - 36:11

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Georg Tikhonov
36:17 - 36:41

A question regarding Japan. As always, I was going to say, in earlier presentations, you have indicated that Japan partnerships might have been expected a bit earlier than we are now in time. What has caused this delay, if we call it that? And have negotiations progressed to commercial terms currently with potential partners?

Sofia Heigis
36:41 - 39:21

So thank you for the question. To remind you of our Japanese history, we started the discussions. To your point, already in, I think it was 2024, even with multiple companies, we progressed very well and quite rapidly. And we decided, once we entered into more sharp discussions, to give one partner exclusivity, as that was demanded. Unfortunately, this company had several delays in the process. And it took a long time. We consistently pressure-tested the situation and believed that we would be able to close the deal with this partner. But at the end of the day, the company unfortunately had a financial issue based on that. One of the products at the company was withdrawn and they put all of their licensing efforts on hold. It had nothing to do with Pepaxti specifically, but rather the situation of that company. And they are still on hold trying to sort their financial situation. And with that, we then initiated a new round of discussions with a new set of partners. And that is where we are now. So I have myself been to Japan twice this year to both initiate new discussions, but also, of course, go deeper into due diligence. . When I was there last time, we progressed with some of the companies that we initiated earlier this year, and I also spoke to the key opinion leaders because we are also progressing in Europe. So now with a potential new label in Europe, we of course wanted to speak to the KOLs to understand whether that potential could also be realized in Japan over time. I am very happy to say that because Japan is quite a hierarchical country, there are just a few top KOLs that are really deciding the treatment landscape, and all of them are very supportive and have promised to educate partners on Pepaxti should it be needed. So from that perspective, we are progressing well as the need is still confirmed. There may be an even greater potential and greater opportunity for Japanese patients. And we have several companies that we are discussing with.

Georg Tikhonov
39:23 - 39:44

Great. Another question. You have reiterated your target of positive cash flow from the commercial business during 2027. Could you clarify whether this target depends on a significant contribution from the third-line expansion, and what approximate quarterly sales level would be required to reach break-even?

Henrik Bergentoft
39:45 - 40:34

Yes. Thank you so much for that question. So perhaps starting with the final part of the question, the cost base that the company is currently running at is pretty much about the commercial operations. So the current running rate cost base is what would be required in revenue to be on a cash flow positive basis for the commercial part of the company. Now with regards to the third-line, our target of becoming cash flow positive was expressed before we got this opportunity to expand ourselves into the third-line. But obviously, this will help reach our target of becoming cash flow positive for sure.

Sofia Heigis
40:35 - 42:18

And just to build on Henrik, I am repeating myself when I say that the market landscape is really evolving. So our position is also changing. That is, the potential in the fourth line is changing as the bispecifics are moving from the fourth line to the second line. But obviously, the position in the third line becomes even stronger based on that move. So I would argue it is difficult to say that what was true when it comes to market dynamics and share per line is also true now because it is changing so much all the time. I see a potential approval in the third-line setting as perfect timing based on how other drugs are moving. So I would not be surprised if we can gain maybe an even higher market share in third line going forward than what we would have expected a year ago. Just to give you a sense of the complexity, but also of what I would argue is the opportunity with the third-line label expansion. So when it comes to, of course, feeding into us becoming cash flow positive. I mean, when the positions are starting to move around, we have to consider the holistic and full picture. And what's really good with Oncopeptides AB is that we have a team that is really seasoned in hematology. They are very well connected to KOLs. I am very well connected to the KOLs. So we can follow the trends very closely. And we are never far away from the insights to understand how the market is changing.

Georg Tikhonov
42:19 - 42:24

Great. That is all the questions we have time for. So Sofia, back to you for any final words.

Sofia Heigis
42:25 - 42:40

I just want to thank everyone for joining us today for the questions and your continued support and interest in Oncopeptides AB. I do believe we have really exciting times ahead, and I wish you a good day.

Katso webcast
Revenio Group Oyj, Q3'26
Kieli: englanti12.11.2026 klo 13.00
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Kieli: englanti12.11.2026 klo 9.00
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Kieli: suomi12.11.2026 klo 8.00
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Kieli: suomi11.11.2026 klo 9.00
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Kieli: englanti10.11.2026 klo 11.00
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Kieli: suomi10.11.2026 klo 10.00
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Kieli: englanti10.11.2026 klo 9.00
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Kieli: englanti9.11.2026 klo 12.00
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Kieli: englanti6.11.2026 klo 12.30
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 13.00
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Kieli: englanti5.11.2026 klo 11.00
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 10.30
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Kieli: englanti5.11.2026 klo 10.00
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 9.00
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Kieli: englanti5.11.2026 klo 8.30
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 8.00
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 7.30
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 12.00
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Kieli: suomi4.11.2026 klo 9.00
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 8.30
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…